添付資料番号 タイトル 著者 掲載紙
[資料5.4: 5] Sequence analysis of the VP4, VP6, VP7 and NSP4 gene products of the bovine rotavirus WC3.
Ciarlet M, Hyser JM, Estes MK.
Virus Genes. 2002; 24:
107-18.
[資料5.4: 6] Immune response of infants and children to low-passage bovine rotavirus (strain WC3).
Clark HF, Furukawa T, Bell LM, Offit PA, Perrella PA, Plotkin SA.
Am J Dis Child. 1986;
140: 350-56.
[資料5.4: 7] WC3 reassortant vaccines in children. Clark HF, Offit PA, Ellis RW, Krah D, Shaw AR, Eiden JJ, et al.
Arch Virol.
1996;Suppl 12:
187-98.
[資料5.4: 8] Rotaviruses. Ciarlet M, Estes MK. In: Bitton G, eds.
Encyclopedia of Environmental Microbiology. New York, U.S.A.: John Wiley & sons; 2002.
p2753-73.
[資料5.4: 9] Rotaviruses. Kapikian AZ, Hoshino
Y, Chanock RM.
In: Knipe DM, Howley PW, eds. Fields Virology, 4th edition.
Philadelphia:
Lippincott-Raven Publishers.;2001.
p1787-833.
[資料5.4: 10] Clinical Study Report: V260: Safety, Tolerability, and Immunogenicity of Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Adults (Protocol 001).
Merck Research Laboratories.
社内資料
[資料5.4: 11] Clinical Study Report: V260: Safety, Immunogenicity, and Efficacy of a Live, Quadrivalent Human- Bovine Rotavirus Reassortant Vaccine in Healthy Infants (Protocol 002).
Merck Research Laboratories.
社内資料
[資料5.4: 12] Clinical Study Report: V260: Safety, Immunogenicity, and Efficacy in Healthy Infants of G1 and G2 Human-Bovine Rotavirus Reassortant Vaccine in a New Buffer/Stabilizer Liquid Formulation (Protocol 003).
Merck Research Laboratories.
社内資料
[資料5.4: 13] Clinical Study Report: V260: Safety and Tolerability of Oral, Live G4 Human-Bovine Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants (Protocol 004).
Merck Research Laboratories.
社内資料
2.5 臨床に関する概括評価 - 77 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 15] Recomendations for the clasification of group a rotaviruses using all 11 genomic RNA segments.
Matthijnssens J, Ciarlet M, Rahman M, Attoui H, Banyai K, Estes MK, et al.
Arch Virol. 2008; 153:
1621-9.
[資料5.4: 16] Lack of association between rotavirus infection and intussusception:
implications for use of attenuated rotavirus vaccines.
Chang EJ, Zangwill KM, Lee H, Ward JI.
Pediatr Infect Dis J.
2002; 21: 97-102.
[資料5.4: 17] Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine.
Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, et al.
Pediatrics. 2009; 124:
465-71.
[資料5.4: 19] Vaccine against rotavirus lowers hospitalizations and emergency visits.
Peek R, Reddy R. Gastroenterology.
2009; 136: 373.
[資料5.4: 20] 世界的に使われているロタウイルス
ワクチン.
中込とよ子、中込治. 臨床検査. 2009; 53:
111-6.
[資料5.4: 21] Clinical Study Report: V260: Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™
hexa in Healthy Infants (Protocol 010).
Merck Research Laboratories.
社内資料
[資料5.4: 22] Clinical Study Report: V-260:
Immunogenicity and Safety of
RotaTeq™ in Healthy Infants in Korea (Protocol 013).
MSD Korea Ltd. 社内資料
[資料5.4: 23] Clinical Study Report, An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine
(RotaTeq®) and a meningococcal group C conjugate (MCC) vaccine in healthy infants.
Sanofi Pasteur MSD S.N.C.
社内資料
[資料5.4: 24] Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4.
Gorziglia M, Larralde G, Kapikian AZ, Chanock RM.
Proc Natl Acad Sci.
1990; 87: 7155-9.
[資料5.4: 25] Analysis of homotypic and heterotypic serum immune responses to rotavirus proteins following primary rotavirus infection by using the
radioimmunoprecipitation technique.
Richardson SC, Grimwood K, Bishop RF.
J Clin Microbiol.
1993; 31: 377-85.
[資料5.4: 28] Intussusception among infants given an oral rotavirus vaccine.
Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al.
N Engl J Med. 2001;
344: 564-72.
[資料5.4: 30] A comparison of the effects of oral inoculation with rotashield and pentavalent reassortant rotavirus vaccine (WC3-PV) on suckling CB17scid mice.
Qiao H, Clark HF, DiVietro M,
Riepenhoff-Talty M.
J Gen Virol. 2004; 85:
2245-53.
2.5 臨床に関する概括評価 - 78 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 32] Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children.
Anderson EL, Belshe RB, Bartram J, Crookshanks-Newman F, Chanock RM, Kapikian AZ.
J Infect Dis. 1986;
153: 823-31.
[資料5.4: 33] Simultaneous administration of two human-rhesus rotavirus reassortant strains of VP7serotype 1 and 2 specificity to infants and young children.
Wright PF, King J, Araki K, Kondo Y, Thompson J, Tollefson SJ, et al.
J Infect Dis. 1991;
164: 271-6.
[資料5.4: 35] Shedding of rotavirus after
administration of the tetravalent rhesus rotavirus vaccine.
Ward RL, Dinsmore AM, Goldberg G, Sander DS, Rappaport RS, Zito ET.
Pediatr Infect Dis J.
1998; 17: 386-90.
[資料5.4: 36] Evaluation of rhesus rotavirus
monovalent and tetravalent reassortant vaccines in US children.
Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA.
JAMA. 1995; 273:
1191-6.
[資料5.4: 37] Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants.
Joensuu J, Koskenniemi E, Vesikari T.
Pediatr Infect Dis J.
1998; 17: 334-40.
[資料5.4: 38] Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4.
Clark HF, Lawley D, Shrager D,
Jean-Guillaume D, Offit PA, Whang SY, et al.
Pediatr Infect Dis J.
2004; 23: 206-11.
[資料5.4: 51] Merck Report: Rotavirus VP4 PCR-serotyping, - -20 .
Merck Vaccine Biometrics Research.
社内資料 [資料5.4: 52] Efficacy and safety of high-dose
rhesus-human reassortant rotavirus vaccine in Native American populations.
Santosham M, Moulton LH, Reid R, Croll J, Weatherbolt R, Ward R, et al.
J Pediatr. 1997; 131:
632-8.
[資料5.4: 53] Serum antibody as a marker of protection against natural rotavirus infection and disease.
Velázquez FR, Matson DO, Guerrero ML, Shults J, Calva JJ, Morrow AL, et al.
J Infect Dis. 2000;
182: 1602-9.
[資料5.4: 54] Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections.
O'Ryan ML, Matson DO, Estes MK, Pickering LK.
J Infect Dis. 1994;
169: 504-11.
[資料5.4: 57] Memo to Drummond JE from Chen J:
Statistical report on the characterization of the human anti-rotavirus (G3) serum neutralization assay using strain OSU 78-8, - -20 .
Merck Vaccine Biometrics Research.
社内資料
[資料5.4: 58] Memo to Drummond J from Chen J:
Characterization of the human antirotavirus serum IgA enzyme immunoassay, - -19 .
Merck Vaccine Biometrics Research.
社内資料
2.5 臨床に関する概括評価 - 79 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 59] Memo to Kniskern P, Shaw A from Chen J: Statistical report on the characterization of the rotavirus neutralization assay, - -19 .
Merck Biometrics Research.
社内資料
[資料5.4: 60] Memo to Drummond JE from Chen J:
Statistical report on the characterization of the human anti-rotavirus serum neutralization assay for type G4 rotavirus, - -19 .
Merck Vaccine Biometrics Research.
社内資料
[資料5.4: 62] Update on intussusception. Orenstein J. Contemp Pediatr.
2000; 17: 180, 185-86, 188-91.
[資料5.4: 69] Rotavirus infection in infants as protection against subsequent infections.
Velázquez FR, Matson DO, Calva JJ,
Guerrero ML, Morrow AL, Carter-Campbell S, et al.
N Engl J Med. 1996;
335: 1022-8.
[資料5.4: 70] Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the national multicenter trial.
Rennels MB, Glass RI, Dennehy PH,
Bernstein DI, Pichichero ME, Zito ET, et al.
Pediatrics. 1996; 97:
7-13.
[資料5.4: 71] MRL Report: Comparison of the rotavirus G3 serotype-specific serum antibody responses in Phase II and Phase III randomized, double-blind, placebo controlled clinical trials of RotaTeq®, 20 .
Ciarlet M, Drummond JE, Green T, Jowlsson DB, Peterson S, Wang S, et al.
社内資料
[資料5.4: 80] An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?
Haber P, Chen RT, Zanardi LR, Mootrey GT, English R, Braun MM, et al.
Pediatrics. 2004; 113:
e353-9.
[資料5.4: 82] ロタウイルス胃腸炎の現状. 中込とよ子、葛谷光
隆、中込治.
化学療法の領域.
2008; 24: 1488-97.
[資料5.4: 83] Pediatric viral gastroenteristis during eight years of study.
Brandt CD, Kim HW, Rodriguez WJ, Arrobio JO, Jefferies BC, Stallings EP, et al.
J Clin Microbio. 1983;
18: 71-8.
[資料5.4: 84] Rotavirus vaccines. Clark HF, Glass RI, Offit PA.
In: Plotkin SA, Orenstein WA, eds.
Vaccines. 3rd ed.
Philadelphia: W.B.
Saunders Company, 1999:987-1005.
[資料5.4: 85] ロタウイルスの最近の話題. 河島尚志、渡邉知愛
子、五百井寛明.
モダンメディア. 2006; 52: 371-6.
[資料5.4: 86] ロタウイルスワクチン. 牛島廣治、石田眞一. 日本臨牀. 2008; 66:
1977-83.
2.5 臨床に関する概括評価 - 80 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 87] The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden.
Glass RI, Kilgore PE, Holman RC, Jin S, Smith JC, Woods PA, et al.
J Infect Dis. 1996; 174 Suppl 1: S5-11.
[資料5.4: 88] Rotavirus vaccination. World Health Organization.
Weekly
epidemiological record 2009;84:232-6.
[資料5.4: 89] わが国にロタウイルスワクチンは必
要か？
中込治、中込とよ子. モダンメディア.
2008; 54: 317-30.
[資料5.4: 90] 世界的に使用されているロタウイル
スワクチンのわが国における必要 性.
中込とよ子、中込治. 臨床とウイルス. 2009; 37: 167-77.
[資料5.4: 91] Incidence and burden of rotavirus gastroenteritis in Japan, as estimated from a prospective sentinel hospital study.
Nakagomi T, Nakagomi O,
Takahashi Y, Enoki M, Suzuki T, Kilgore PE.
J Infect Dis 2005;192 Suppl 1:S106-10.
[資料5.4: 92] Global illness and deaths caused by rotavirus disease in children.
Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI.
Emerg Infect Dis.
2003; 9: 565-72.
[資料5.4: 93] Full genome-based classification of rotaviruses reveals a common origin between human Wa-like and porcine rotavirus strains and human DS-1-like and bovine rotavirus strains.
Matthijnssens J, Ciarlet M, Heiman E, Arijs I, Delbeke T, McDonald SM, et al.
J. Virol.2008; 82:
3204-19.
[資料5.4: 94] ロタウイルス感染症の臨床像とワク
チン開発.
谷口孝喜. 小児科. 2007; 48:
1361-8.
[資料5.4: 95] Molecular analysis of the VP7 gene of pheasant rotaviruses identifies a new genotype, designated G23.
Ursu K, Kisfali P, Rigo D, Ivanics E, Erdelyi K, Dan A, et al.
Arch Virol. 2009;
154:1365–9.
[資料5.4: 96] Identification of a novel VP4 genotype carried by a serotype G5 porcine rotavirus strain.
Martella V, Ciarlet M, Bányai K, Lorusso E, Cavalli A, Corrente M, et al.
Virology. 2006;
346:301-11.
[資料5.4: 97] Identification of Group A Porcine Rotavirus Strains Bearing a Novel VP4 (P) Genotype in Italian Swine Herds.
Martella V, Ciarlet M, Bányai K, Lorusso E, Arista S, Lavazza A, et al.
J Clin Microbiol.
2007; 45:577-80.
[資料5.4: 98] Characterization of novel VP7, VP4, and VP6 genotypes of a previously untypeable group A rotavirus.
Solberg OD, Hasing ME, Trueba G, Eisenberg JNS.
Virology.
2009;385:58-67.
[資料5.4: 99] Evidence of interspecies transmission and reassortment among avian group A rotaviruses.
Schumann T, Hotzel H, Otto P, Johne R.
Virology.
2009;386:334-43.
[資料5.4: 100] The first complete genome sequence of a chicken group A rotavirus indicates independent evolution of mammalian and avian strains.
Trojnar E, Otto P, Johne R.
Virology.
2009;386:325-33.
2.5 臨床に関する概括評価 - 81 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 101] Global distribution of rotavirus serotypes/genotypes and its implication for the development and
implementation of an effective rotavirus vaccine.
Santos N, Hoshino Y. Rev Med Virol. 2005;
15: 29-56.
[資料5.4: 102] Rotavirus disease and its prevention. Widdowson M-A, Bresee JS, Gentsch JR, Glass RI.
Current Opinion in Gastroenterology.
2005; 21: 26-31.
[資料5.4: 103] Rotaviruses. Kapikian AZ, Chanock
RM.
In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields Virology. 3rd ed.
Philadelphia:
Lippincott - Raven Publishers;
1996:1657-708.
[資料5.4: 104] Viral gastrointestinal infections. Kapikian AZ, Wyatt RG.
In: Kapikian AZ, Wyatt RG, eds.
Textbook of Pediatric Diseases. 3rd ed.
Philadelphia (PA):
Philadelphia: Saunders 1992, 1992:655-76.
[資料5.4: 105] Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children.
Rodriguez WJ, Kim HW, Arrobio JO, Brandt CD, Chanock RM, Kapikian AZ, et al.
J Pediatr. 1977; 91:
188-93.
[資料5.4: 106] Vaccines for rotavirus gastroenteritis universally needed for infants.
Clark HF, Offit PA. Pediatr Ann. 2004; 33:
537-43.
[資料5.4: 107] Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico.
Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B,
Gomez-Altamirano CM, et al.
N Engl J Med 2010;362:299-305.
[資料5.4: 108] Diarrhea morbidity and mortality in Mexican children: impact of rotavirus disease.
Velázquez FR, Garcia-Lozano H, Rodriguez E, Cervantes Y, Gómez A, Melo M, et al.
Pediatr Infect Dis J 2004;23:S149-55.
[資料5.4: 109] Mechanisms of protection against rotavirus in humans and mice.
Ward RL. J Infect Dis 1996;174 Suppl 1:S51-8.
[資料5.4: 110] Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals.
O'Ryan M, Pérez-Schael I, Mamani N, Peña A, Salinas B, González G, et al.
Pediatr Infect Dis J.
2001;20:685-93.
2.5 臨床に関する概括評価 - 82 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 111] Development of a rotavirus vaccine:
Clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq®.
Ciarlet M, Schödel F Vaccine. 2009; 27S:
G72-81.
[資料5.4: 112] Rotavirus infection and rates of hospitalisation for acute gastroenteritis in young children in Australia, 1993-1996.
Carlin JB, Chondros P, Masendycz P, Bugg H, Bishop RF, Barnes GL.
Med J Aust. 1998;
169: 252-6.
[資料5.4: 113] The protective effectiveness of natural rotavirus infection in an American Indian population.
Moulton LH, Staat MA, Santosham M, Ward RL.
J Infect Dis 1998;178:1562-6.
[資料5.4: 114] ロタウイルスワクチン. 谷口孝喜. 小児科診療. 2007; 12:
2283-7.
[資料5.4: 115] 日本におけるロタウイルスワクチン
の薬剤経済分析.
折原慎弥、五十嵐中、
鈴木宏、福田敬、津 谷喜一郎.
日本薬学会第129年 会 京都 2009 3/26.
[資料5.4: 116] Costs of community-acquired pediatric rotavirus gastroenteritis in 7 european countries: the REVEAL Study.
Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen M.
J Infect Dis 2007; 195 Suppl 1: S36–44.
[資料5.4: 117] Cost-effectiveness of introducing a rotavirus vaccine in developing countries: The case of Mexico.
Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R.
BMC Infectious Diseases 2008, 8:103.
[資料5.4: 118] Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine.
Nakagomi T, Cuevas LE, Gurgel RG, Elrokhsi SH, Belkhir YA, Abugalia M, et al.
Arch Virol.
2008;153:591–3.
[資料5.4: 119] Two year review of intestinal intussusception in six large public hospitals of Santiago, Chile.
O'Ryan M, Lucero Y, Peña A, Valenzuela MT.
Pediatr Infect Dis J.
2003; 22: 717-21.
[資料5.4: 120] Trends in intussusception-associated hospitalizations and deaths among US infants.
Parashar UD, Holman RC, Cummings KC, Staggs NW, Curns AT, Zimmerman CM, et al.
Pediatrics. 2000; 106:
1413-21.
[資料5.4: 121] Rotavirus vaccination and
intussusception [correspondence].
Gay N, Ramsay M, Waight P.
Lancet. 1999; 354:
956.
[資料5.4: 122] Epidemiology and clinical features of intussusception (IS) in children <24 months of age in Hamilton County, Ohio [Abstract].
Staat MA, Roberts NE, Bernstein DI.
Infectious Diseases.
2001; 242A.
[資料5.4: 123] Lack of an apparent association between intussusception and wild or vaccine rotavirus infection.
Rennels MB, Parashar UD, Holman RC, Le CT, Chang H-G, Glass RI, et al.
Pediatr Infect Dis J.
1998; 17: 924-5.
[資料5.4: 124] ロタウイルス感染と腸重積症. 中込とよ子. 臨床とウイルス.
2003; 31: 170-8.
[資料5.4: 125] Intussusception in infants and children. Ravitch MM. Springfield (IL):
Charles C. Thomas;
1959:3-27.
2.5 臨床に関する概括評価 - 83 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 126] Intussusception revisited:
Clinicopathologic analysis of 261 cases, with emphasis on pathogenesis.
Pang L-C. South Med J. 1989; 82:
215-28.
[資料5.4: 127] Intussusception: A 9-year survey (1986-1995).
Eshel G, Barr J, Heyman E, Tauber T, Klin B, Vinograd I, et al.
J Pediatr Gastroenterol Nutr. 1997; 24: 253-6.
[資料5.4: 128] A high incidence of intussusception in Japan as studied in a sentinel hospital over a 25-year period (1978-2002).
Nakagomi T,
Takahashi Y, Arisawa K, Nakagomi O.
Epidemiol. Infect.
2006; 134:57-61.
[資料5.4: 129] Intussusception: Issues and
controversies related to diagnosis and reduction.
Daneman A, Alton DJ. Pediatric Gastrointestinal Radiology. 1996; 34:
743-56.
[資料5.4: 130] Intussusception in children: Current concepts in diagnosis and enema reduction.
del-Pozo G, Albillos JC, Tejedor D, Calero R, Rasero M,
de-la-Calle U, et al.
Radiographics. 1999;
19: 299-319.
[資料5.4: 131] Intussusception in the 1990s: has 25 years made a difference?
Ein SH, Alton D, Palder SB, Shandling B, Stringer D.
Pediatr Surg Int. 1997;
12: 374-6.
[資料5.4: 132] Colon and rectum. Haubrich WS,
Schaffner F.
In: Berk JE, eds.
Gastroenterology.
Volume 1. 5th ed.
Philadelphia (PA):
W.B. Saunders Company; 1995:192-8.
[資料5.4: 133] Spontaneous reduction of
intussusception: clinical spectrum, management and outcome.
Kornecki A, Daneman A, Navarro O, Connolly B, Manson D, Alton DJ.
Pediatr Radiol. 2000;
30: 58-63.
[資料5.4: 134] Intussusception, adenovirus, and children: A brief reaffirmation.
Montgomery EA, Popek EJ.
Hum Pathol. 1994; 25:
169-74.
[資料5.4: 135] Adenovirus and intranuclear inclusions in appendices in intussusception.
Porter HJ, Padfield CJH, Peres LC, Hirschowitz L, Berry PJ.
J Clin Pathol. 1993;
46: 154-8.
[資料5.4: 136] Viral etiology of intussusception in Taiwanese childhood.
Hsu H-Y, Kao C-L, Huang L-M, Ni Y-H, Lai H-S, Lin F-Y, et al.
Pediatr Infect Dis J.
1998; 17: 893-8.
[資料5.4: 137] A one-year virological survey of acute intussusception in childhood.
Nicolas JC, Ingrand D, Fortier B, Bricout F.
J Med Virol. 1982; 9:
267-71.
[資料5.4: 138] A two-part study of the aetiological role of rotavirus in intussusception.
Mulcahy DL, Kamath KR, de Silva LM, Hodges S, Carter IW, Cloonan MJ.
J Med Virol. 1982; 9:
51-5.
2.5 臨床に関する概括評価 - 84 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 139] Human rotavirus infection in infants and young children with
intussusception.
Konno T, Suzuki H, Kutsuzawa T, Imai A, Katsushima N, Sakamoto M, et al.
J Med Virol. 1978; 2:
265-9.
[資料5.4: 140] Extramucosal spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus.
Uhnoo I,
Riepenhoff-Talty M, Dharakul T, Chegas P, Fisher JE, Greenberg HB, et al.
J Virol. 1990; 64:
361-8.
[資料5.4: 141] Kawasaki syndrome hospitalizations in the United States, 1997 and 2000.
Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB.
Pediatrics
2003;112:495-501.
[資料5.4: 142] 第20回川崎病全国調査成績 2009年9 月.
特定非営利活動法人 日本川崎病研究セン ター 川崎病全国調 査担当グループ.
-
[資料5.4: 143] Kawasaki syndrome. Rowley AH. In: Gershon AA, Hotez PJ, Katz SL, eds.
Krugman’s infectious diseases of children.
11th edition.
Philadelphia: Mosby 2004:323-35.
[資料5.4: 144] Kawasaki disease: Etiology, pathogenesis, and treatment.
Barron KS. Cleve Clin J Med.
2002;69 Suppl II:SII69-78.
[資料5.4: 145] 川崎病（MCLS、小児急性熱性皮膚
粘膜リンパ節症候群）診断の手引き.
（厚生労働省川崎病 研究班作成改訂5版）
2002年2月
-
[資料5.4: 146] Association of rotavirus infection with Kawasaki syndrome.
Matsuno S, Utagawa E, Sugiura A.
J Infect Dis.
1983;148:177.
[資料5.4: 147] Clinical Study Report: V260: Efficacy, safety and immunogenicity study of RotaTeq™ among infants in Asia and Africa. (Protoacol 015)
Merck Research Laboratories.
社内資料
[資料5.4: 148] Clinical Study Report, Evaluation of Safety, Tolerability and
Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India (Protocol 021).
MSD Pharmaceuticals. 社内資料
[資料5.4: 149] Extended excretion of
rotavirus after severe diarrhoea in young children.
Richardson S, Grimwood K, Gorrell R, Palombo E, Barnes G, Bishop R.
Lancet
1998;351:1844-8.
[資料5.4: 150] Faecal and pharyngeal shedding of rotavirus and rotavirus
IgA in children with diarrhoea.
Stals F, Walther FJ, Bruggeman CA.
J Med Virol 1984;14:333-9.
2.5 臨床に関する概括評価 - 85 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 151] Rotavirus. Parashar UD, Bresee
JS, Gentsch JR, Glass RI.
Emerg Infect Dis 1998;4:561-70.
[資料5.4: 152] Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.
Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J, et al.
Vaccine. 2004; 22:
569-74.
[資料5.4: 153] Rotavirus and central nervous system symptoms: Cause or contaminant? Case report and review.
Lynch M, Lee B, Azimi P, Gentsch J, Glaser C, Gilliam S, et al.
Clin Infect Dis, 2001;
33: 932-8.
[資料5.4: 154] Rotavirus gastroenteritis and central nervous system (CNS) infection:
Characterization of the VP7 and VP4 genes of rotavirus strains isolated from paired fecal and cerebrospinal fluid samples from a child with CNS disease.
Iturriza-Gómara M, Auchterlonie IA, Zaw W, Molyneaux P, Desselberger U, Gray J.
J Clin Microbio. 2002;
40: 4797-9.
[資料5.4: 155] Detection of rotavirus in cerebrospinal fluid and blood of patients with convulsions and gastroenteritis by means of the reverse transcription polymerase chain reaction.
Nishimura S, Ushijima H, Nishimura S, Shiraishi H, Kanazawa C, Abe T, et al.
Brain Dev. 1993; 15:
457-9.
[資料5.4: 156] Rotaviral gastrointestinal infection causing afebrile seizures in infancy and childhood.
Contino MF, Lebby T, Arcinue EL.
Am J Emerg Med.
1994; 12: 94-5.
[資料5.4: 157] Rotavirus encephalopathy: Evidence of central nervous system involvement during rotavirus infection.
Keidan I, Shif I, Keren G, Passwell JH.
Pediatr Infect Dis J.
1992; 11: 773-5.
[資料5.4: 158] Rotavirus encephalitis mimicking afebrile benign convulsions in infants.
Hongou K, Konishi T, Yagi S, Araki K, Miyawaki T.
Pediatric Neurology.
1998; 18: 354-7.
[資料5.4: 159] Rotavirus associated with poliomyelitis-like syndrome.
Chou I-C, Tsai C-H, Tsai F-J.
Pediatr Infect Dis J.
1998; 17: 930-1.
[資料5.4: 160] Acute myositis with transient decrease of albumin, immunoglobulin, and complement following rotavirus gastroenteritis.
Bonno M, Higashigawa M, Nakano T, Miyahara M, Azuma E, Komada Y, et al.
Acta Paediatrica Japonica. 1998; 40:
82-4.
[資料5.4: 161] Serum aspartate aminotransferase levels after rotavirus gastroenteritis.
Grimwood K, Coakley JC, Hudson IL, Bishop RF, Barnes GL.
J Pediatr. 1988; 112:
597-600.
[資料5.4: 162] Human rotavirus-like particles in a hepatic abscess.
Granow JE, Dunton SF, Waner JL.
J Pediatr. 1985; 106:
73-6.
2.5 臨床に関する概括評価 - 86 -
添付資料番号 タイトル 著者 掲載紙
[資料5.4: 163] A novel rotavirus vaccine RIX4414 is not associated with intussusception [abstract].
O'Ryan M, Lanata C, Abate H, Schael IP, Rivera M, Ortega E, et al.
44th Interscience Conference on Antimicrobial Agents and
Chemotherapeutics (ICAAC); 2004 Oct 30-Nov-02.
Washington (DC), 2004:15.
[資料5.4: 164] Chronic enteric virus infection in two t-cell immunodeficient children.
Wood DJ, David TJ, Chrystie IL, Totterdell B.
J Med Virol. 1988; 24:
435-44.
[資料5.4: 165] Serial observations of chronic rotavirus infection in an immunodeficient child.
Oishi I, Kimura T, Murakami T, Haruki K, Yamazaki K, Seto Y, et al.
Microbiol Immunol.
1991; 35: 953-61.
[資料5.4: 166] Clinical features of nosocomial rotavirus infection in pediatric liver transplant recipients.
Fitts SW, Green M, Reyes J, Nour B, Tzakis AG, Kocoshis SA.
Clin Transplantation.
1995; 9: 201-4.
[資料5.4: 167] MRL Report: V260: Protocol 005,
"Safety, immunogenicity, and efficacy in healthy infants of G1, G2, G3, G4, and P1 human-bovine rotavirus reassortant vaccine" - evaluation of safety data in subjects that were greater than or equal to 6 months of age at the first dose, - -20 .
Merck Research Laboratories.
社内資料
[資料5.4: 168] 平成20年度診療報酬改定の基本方針
（平成19年12月3日）.
社会保障審議会医療 保険部会、社会保障 審議会医療部会.
-
[資料5.4: 169] 診療報酬改定結果検証に係る特別調
査（平成20年度調査）;病院勤務医の 負担軽減の実態調査 報告書（案）;
中医協 検-2-1 21.4.22.
中央社会保険医療協 議会.
-